EC
EcoR1 Capital Portfolio holdings
AUM
$1.69B
This Quarter Return
+42.34%
1 Year Return
+7.54%
3 Year Return
+113.08%
5 Year Return
+306.58%
10 Year Return
+4,328.75%
AUM
$1.34B
AUM Growth
+$1.34B
(+40%)
Cap. Flow
+$131M
Cap. Flow
% of AUM
9.78%
Top 10 Holdings %
Top 10 Hldgs %
61.12%
Holding
70
New
18
Increased
13
Reduced
7
Closed
23
Top Buys
| 1 |
Oric Pharmaceuticals
ORIC
|
$89.1M |
| 2 |
Xencor
XNCR
|
$66.3M |
| 3 |
Avidity Biosciences
RNA
|
$59.5M |
| 4 |
AKUS
Akouos, Inc. Common Stock
AKUS
|
$44.5M |
| 5 |
Geron
GERN
|
$41.9M |
Top Sells
| 1 |
Arvinas
ARVN
|
$61.6M |
| 2 |
Fate Therapeutics
FATE
|
$59.1M |
| 3 |
Ironwood Pharmaceuticals
IRWD
|
$44.3M |
| 4 |
FibroGen
FGEN
|
$30.7M |
| 5 |
IPHA
Innate Pharma
IPHA
|
$29.8M |
Sector Composition
| 1 | Healthcare | 93.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Xencor
XNCR
$580M
| $147M | 10.88% | 4,547,072 +2,045,515 | +82% | +$66.3M |
|
2
Prothena Corp
PRTA
$441M
| $98.6M | 7.28% | 9,426,640 | – | – |
|
|
3
Oric Pharmaceuticals
ORIC
$994M
| $89.1M | 6.58% | +2,642,218 | New | +$89.1M |
|
|
MORF
4
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $76.8M | 5.67% | 2,837,973 +14,832 | +0.5% | +$401K |
|
5
Kura Oncology
KURA
$686M
| $75.1M | 5.55% | 4,608,529 +1,096,839 | +31% | +$17.9M |
|
6
Assembly Biosciences
ASMB
$190M
| $73.5M | 5.43% | 3,153,797 +563,117 | +22% | +$13.1M |
|
|
DRNA
7
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $69.1M | 5.11% | 2,721,993 -624,308 | -19% | -$15.9M |
|
8
AnaptysBio
ANAB
$569M
| $68.7M | 5.07% | 3,075,014 +39,000 | +1% | +$871K |
|
|
9
Avidity Biosciences
RNA
$5.99B
| $59.5M | 4.39% | +2,103,950 | New | +$59.5M |
|
10
Neurogene
NGNE
$264M
| $58.7M | 4.34% | 3,536,684 -156,519 | -4% | -$2.6M |
|
11
Arcus Biosciences
RCUS
$1.13B
| $44.8M | 3.31% | 1,810,000 +1,517,900 | +520% | +$37.6M |
|
|
AKUS
12
DELISTED
Akouos, Inc. Common Stock
AKUS
| $44.5M | 3.28% | +1,975,984 | New | +$44.5M |
|
|
13
Geron
GERN
$893M
| $41.9M | 3.1% | +19,230,769 | New | +$41.9M |
|
|
MRTX
14
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $40.9M | 3.02% | 357,849 | – | – |
|
15
Ultragenyx Pharmaceutical
RARE
$2.89B
| $40.6M | 3% | 519,119 +147,911 | +40% | +$11.6M |
|
|
SURF
16
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| $33M | 2.44% | 5,033,861 +3,759,398 | +295% | +$24.7M |
|
|
BCEL
17
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| $31.7M | 2.34% | 1,489,185 +383,005 | +35% | +$8.15M |
|
|
AMTI
18
DELISTED
Applied Molecular Transport Inc. Common Stock
AMTI
| $28.9M | 2.14% | +1,150,000 | New | +$28.9M |
|
|
CNST
19
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $25.2M | 1.86% | +837,885 | New | +$25.2M |
|
|
20
Fate Therapeutics
FATE
$120M
| $21.3M | 1.57% | 619,855 -1,722,020 | -74% | -$59.1M |
|
21
Denali Therapeutics
DNLI
$2.23B
| $17.7M | 1.31% | 733,561 +35,460 | +5% | +$857K |
|
|
BMY.RT
22
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $17M | 1.26% | 4,748,300 +2,500,000 | +111% | +$8.95M |
|
23
Cyclerion Therapeutics
CYCN
$7.91M
| $16.2M | 1.2% | 2,742,276 | – | – |
|
24
Fulcrum Therapeutics
FULC
$351M
| $16.1M | 1.19% | +882,353 | New | +$16.1M |
|
25
Crinetics Pharmaceuticals
CRNX
$2.92B
| $15.1M | 1.11% | 859,802 +509,802 | +146% | +$8.93M |
|